Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer (NATT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00912444
Recruitment Status : Terminated (TAC treatment was associated with better survial outcome compared with TC treatment, we terminated recruiting and waiting for longer follow up period.)
First Posted : June 3, 2009
Last Update Posted : November 22, 2016
Sponsor:
Information provided by (Responsible Party):
Kunwei Shen, Shanghai Jiao Tong University School of Medicine

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : May 2012
Actual Study Completion Date : October 2015